The Technical Analyst
Titan Pharmaceuticals Inc [TTNP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Titan Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.33% $6.97
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.37 mill |
| EPS: | -7.41 |
| P/E: | -0.940 |
| Earnings Date: | Mar 31, 2024 |
| SharesOutstanding: | 0.914 mill |
| Avg Daily Volume: | 0.0109 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.940 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.16x |
| Company: PE -0.940 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.22 (-10.73%) $-0.748 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.21 - 7.73 ( +/- 10.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-02 | Mokhtar Firdauz | Sell | 0 | Common Stock |
| 2024-04-02 | Flores Francisco | Sell | 0 | Common Stock |
| 2024-03-18 | Choong Choon Hau | Buy | 54 132 | Common Stock |
| 2024-03-18 | Choong Choon Hau | Sell | 0 | Convertible Promissory Note |
| 2023-10-25 | Natan David | Buy | 16 250 | Common Stock |
| INSIDER POWER |
|---|
| -84.83 |
| Last 97 transactions |
| Buy: 7 283 197 | Sell: 21 662 130 |
Forecast:
12:32 - $6.96
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $6.97 (-3.33% ) |
| Volume | 0.0026 mill |
| Avg. Vol. | 0.0109 mill |
| % of Avg. Vol | 23.72 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TTNP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TTNP
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Latest Press Releases
2024-01-25 16:29:00 - Press Release
Titan Pharmaceuticals Fully Compliant With Nasdaq Listing Criteria
South san francisco, calif., jan. 25, 2024 (globe newswire) -- titan pharmaceuticals, inc. (nasdaq: ttnp) (“titan” or the “company”) today announced that by letter dated january 24, 2024, the company was notified by the nasdaq stock market llc that the company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on the nasdaq capital market. as such, the listing matter has been closed.
2023-12-28 16:15:00 - Press Release
Titan Pharmaceuticals Announces Reverse Stock Split And Ratio
South san francisco, calif., dec. 28, 2023 (globe newswire) -- titan pharmaceuticals, inc. (nasdaq: ttnp) (“titan” or the “company”) today announced that its board of directors has approved a 1-for-20 reverse stock split of the company's common stock, which will be effective following the filing of an amendment to the company's amended and restated certificate of incorporation (the “amendment”). the company's stockholders approved the reverse stock split at a special meeting of stockholders on december 27, 2023. the company's shares will begin trading on a split-adjusted basis on the nasdaq capital market following the filing of the amendment, which is intended go effective on january 9, 2024.
2023-10-16 16:37:00 - Press Release
Titan Pharmaceuticals Announces Appointment Of Dato' Seow Gim Shen And Brynner Chaim To The Company's Board Of Directors
San francisco, oct. 16, 2023 (globe newswire) -- titan pharmaceuticals, inc. (nasdaq: ttnp) ("titan" or the "company") is pleased to announce the appointments of dato' seow gim shen and brynner chiam to the company's board of directors, effective october 12, 2023. mr. shen has also been appointed chairman of the board.
2023-09-18 07:30:00 - Press Release
Titan Pharmaceuticals Announces $9.5 Million Private Placement Of Convertible Preferred Stock
San francisco, sept. 18, 2023 (globe newswire) -- titan pharmaceuticals, inc. (nasdaq: ttnp) ("titan" or the "company") announced today that it has entered into a definitive securities purchase agreement (the “purchase agreement”) with the sire group ltd. (“sire group”) for the sale of the company's newly designated series aa convertible preferred stock (the “preferred stock”). sire group purchased 950,000 shares of preferred stock for an aggregate purchase price of $9,500,000, consisting of (i) $5 million in cash at closing and (ii) $4.5 million in the form of a promissory note from sire group, personally guaranteed by a principal of sire group, due and payable on september 23, 2023, subject to two 10-day extensions...
2023-07-27 07:30:00 - Press Release
Titan Pharmaceuticals Announces Sale Of Certain Proneura Assets
Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net sales company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net sales
Latest News
2022-07-10 16:00:00 - PennyStocks
Which Industries Are Penny Stocks Investors Watching Right Now
Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-08 10:00:00 - PennyStocks
What to Know About Buying Penny Stocks on July 8th
Here's what you need to know about trading penny stocks on July 8th The post What to Know About Buying Penny Stocks on July 8th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-05 09:15:11 - PennyStocks
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-02-02 12:27:17 - Benzinga
Titan Pharmaceuticals Raises $5.5M Via Equity
Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.
2021-06-23 08:00:00 - PRNewsWire
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus
SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment of moderate-to-severe chronic pruritus (itch).
2021-03-31 16:30:00 - PRNewsWire
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC").
2021-02-18 08:58:16 - Pulse2
TTNP Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is trading at over 15% pre-market. This is why it happened.
2021-02-01 07:30:00 - PRNewsWire
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed...
2021-01-15 09:15:00 - PRNewsWire
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a...
2020-11-30 12:50:00 - PRNewsWire
Titan Pharmaceuticals Announces Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m....